Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Comment by Inca2020on Nov 18, 2020 10:33am
87 Views
Post# 31921851

RE:Cheeky

RE:Cheeky

Here is an update on Tigris 
 

Tigris Trial 

The Company continues to focus on finalizing the Tigris trial within the reasonably shortest timelines, and has implemented mitigation strategies to reduce or eliminate the timing delays due to COVID-19, including: 

  • August 2020 – United States Federal Food and Drug Agency ( “FDA” ) approved a protocol amendment to Spectral’s Tigris trial allowing for an increase in the number of clinical sites to 15 from the 10 in the initial protocol. The increase in number of sites should have a positive impact with access to a potentially much larger population of eligible patients. 
  • September 2020 – All nine Tigris sites resumed their research activities and were actively screening. 
  • November 2020 – The Company has eleven Tigris sites initiated, and has identified remaining sites to increase to fifteen clinical sites.

AmorFatiforlife wrote: Which cheeky fella bought 9 shares for $3.6 today... Lol.. guess everyone has their own strategies. We should be due for a tigris trial update one of these days...maybe a Christmas present to us long term holders. Have a great day all Regards

 

<< Previous
Bullboard Posts
Next >>